Zentalis Pharmaceuticals, Inc.
Reports in 17d· 2026-05-14
+45.1% · 90d
$4.25
+0.27 (+6.78%)
After-Hours $4.26(+0.01)
News
(1)April 2026
Zentalis Pharmaceuticals, Inc. — 8-K Filing
ZNTLZentalis Pharmaceuticals, Inc.
# 🧾 What This Document Is This isn't a standard financial report. It's a **corporate presentation** from Zentalis, attached to a required SEC filing (Form 8-K). Think of it as the company's official slide deck for investors. Its goal is to explain their science, clinical progress, and future plans
Read summaryView on SEC EDGAR
Peers in Biotechnology
VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%